桡骨远端骨折干骺端粉碎性骨折:继发性脆性骨折的预测因素及骨质疏松治疗的作用
这项回顾性队列研究纳入2018年7月至2022年12月单中心接受手术的134例50岁及以上桡骨远端骨折患者,按有无干骺端粉碎性骨折分为两组。干骺端粉碎性骨折组继发性骨折发生率为17.8%,显著高于无粉碎性骨折组的3.4%(p=0.004),干骺端粉碎性骨折与继发性骨折风险增加5.2倍相关(HR 5.2,95%CI 1.4-10.7,p=0.004)。联合骨质疏松治疗(活性维生素D联合双膦酸盐或促骨形成药物)组继发性骨折率显著低于单用维生素D组(5.6% vs 15.4%,p=0.046)。
要点
- 干骺端粉碎性骨折组继发性骨折率为17.8%,显著高于无粉碎性骨折组的3.4%(p=0.004)。
- 干骺端粉碎性骨折与继发性骨折风险增加5.2倍相关(HR 5.2,95%CI 1.4-10.7,p=0.004)。
- 联合骨质疏松治疗组继发性骨折率显著低于单用维生素D组(5.6% vs 15.4%,p=0.046)。
核心结论
- 桡骨远端骨折患者的干骺端粉碎性骨折显著升高继发性骨折风险;联合骨质疏松治疗可能降低这一风险。
研究设计与样本
- 回顾性队列研究,纳入2018年7月至2022年12月单中心接受桡骨远端骨折手术的134例50岁及以上患者,按有无干骺端粉碎性骨折分为粉碎性骨折组(n=45)和无粉碎性骨折组(n=89),主要结局为继发性骨折发生率,采用多变量Cox模型校正年龄、性别、体重指数、骨密度、骨质疏松治疗类型和痴呆。
主要发现
- 粉碎性骨折组继发性骨折发生率为17.8%,无粉碎性骨折组为3.4%,两组差异显著(p=0.004)。
- 干骺端粉碎性骨折与继发性骨折风险增加5.2倍相关(HR 5.2,95%CI 1.4-10.7,p=0.004)。
- 联合治疗组(活性维生素D联合双膦酸盐或促骨形成药物)继发性骨折率为5.6%,单用维生素D组为15.4%,两组差异显著(p=0.046)。
临床怎么用
- 作者认为,干骺端粉碎性骨折应作为骨折风险分层的重要依据,高风险桡骨远端骨折患者需要强有力的骨质疏松管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Metaphyseal comminution in distal radius fracture (DRF) cases might indicate severe osteoporosis. The patients with DRFs and metaphyseal comminution showed 5.2-fold increased secondary fractures compared with those receiving combination osteoporosis therapy. High-risk DRF patients require aggressive osteoporosis management and fracture risk stratification. PURPOSE: Distal radius fractures (DRFs) are common in patients with osteoporosis and associated with increased risks for subsequent fractures. Metaphyseal comminution in patients with DRFs may indicate severe osteoporosis and heightened bone fragility. However, its relationship with the risk of secondary fragility fractures remains unclear. This study aimed to evaluate the incidence of secondary fractures in patients with DRFs involving metaphyseal comminution and assess the effectiveness of osteoporosis treatment in reducing this risk. METHODS: In this retrospective cohort study, 134 patients aged ≥ 50 years underwent DRF surgery at a single institution from July 2018 to December 2022. The patients were allocated into groups by the presence (n = 45) or absence (n = 89) of metaphyseal comminution. The primary outcome was secondary fracture incidence. A multivariate Cox model was used, adjusting for age, sex, body mass index, bone mineral density, osteoporosis treatment type, and dementia. RESULTS: Secondary fractures were significantly more frequent in the comminution group (17.8%) than in the non-comminution group (3.4%) (p = 0.004). Metaphyseal comminution was associated with 5.2-fold increased secondary fracture risk (hazards ratio: 5.2, 95% confidence interval: 1.4-10.7, p = 0.004). The patients administered combination therapy (active vitamin D plus bisphosphonates or anabolic agents) had notably lower secondary fracture rate than did those receiving vitamin D alone (5.6% vs. 15.4%, p = 0.046). CONCLUSIONS: Metaphyseal comminution in patient with DRFs significantly elevated secondary fracture risk; combination osteoporosis therapy might mitigate this risk. These findings underscore the need for robust osteoporosis management in high-risk patients, suggesting metaphyseal comminution should be crucial for fracture risk stratification.
引用
- Kawamura K, Murata S, Kitano Y, et al. Metaphyseal comminution in distal radius fractures: a predictor of secondary fragility fractures and the role of osteoporosis treatment. Osteoporos Int. 2025. PMID: 39873745. doi:10.1007/s00198-025-07404-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。